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Thirty eight observational studies from 14 countries were included. Classification 
of outbreaks by setting was straightforward: 29 outbreaks occurred over a territory 
(country, region, city, etc.), 4 outbreaks in a school, 2 outbreaks at hospital, 2 in an 
isolated community and 1 at university. Costs included in this study were costs 
incurred in controlling the outbreak. Treatments with antibiotics or prophylaxis 
were reported in 10 references covering all settings. GP or specialist visits were 
reported in 3 articles (2 outbreaks over a territory and 1 outbreak in a school). Finally 
22 references reported information on hospitalisations: hospitalisation rates ranged 
from 0% to 8.8% for cases of pertussis (in 2 references, no hospitalisation occurred 
in the population exposed to the outbreak). Length of stay was reported in 2 refer-
ences: 8.9 days in hospital and 13 days in paediatric intensive care unit considering 
an outbreak at hospital, and 4 days (1 to 48 days) over a territory. CONCLUSIONS: 
The extent and the management of outbreaks differed by setting, and the economic 
burden of pertussis outbreaks was not always comparable. Nevertheless this review 
shows that the burden may be substantial.
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OBJECTIVES: Heterosexual transmission has become the major HIV transmission 
route in Guangxi China. Studies in this region reveal new cases of males newly 
infected with HIV that were both heterosexual and elderly. This study aims to 
understand the association of unsafe sex behaviors with HIV infection among 
the male clients who purchase commercial sex in in low-cost sex venues of 
Guangxi. METHODS: A cross-sectional survey study was conduct in 13 regions of 
Guangxi, among male commercial sex clients who were over 50 years old in low-
cost sex venues during October to December of 2012. Participants were interviewed 
with structured questionnaire, and had blood drawn for HIV testing. Univariate and 
multiple logistic regression models were used for data analysis. RESULTS: 3485 
participants were recruited with all blood samples tested for HIV infection. The 
prevalence of HIV in this sample was 2.96%. The risk factors associated with HIV 
infection included: being single/divorced/separated/widower (AOR:1.77, 95%CI: 1.17-
2.67, P< 0.05); aphrodisiac use (AOR:1.71, 95%CI: 1.14-2.58, P< 0.05); non-condom use 
during commercial purchased sex (AOR: 1.83, 95%CI: 1.21-2.76, P< 0.05). Also, the time 
line of last purchase of commercial is correlated to HIV infection, and the significant 
risk factor was within the last 7 days (1 week ) (AOR: 1.83, 95%CI: 1.21-2.76, P< 0.05). 
The health history of a chronic diseases was found to be a protective factor (AOR: 
0.59, 95%CI: 0.37-0.94, P< 0.05). CONCLUSIONS: Given that the high prevalence of 
HIV infection among the study group, more political policy interventions should be 
a consideration of focus with the subpopulation (middle-aged, elderly men, aphro-
disiacs and non-condom use) in rural areas of this region.
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OBJECTIVES: The cost of new HCV treatments leads payers and insurance provid-
ers to question if delaying treatment for low risk patients can be accomplished 
without adversely impacting their clinical outcome. Retrospective cohort data from 
the Veterans Administration [VA] were used to estimate the impact on patient risk 
of initiating treatment before versus after the patient’s FIB4 levels became ele-
vated. METHODS: Essentially all VA HCV patients with one or more reported FIB-4 
values during the study period were included in the analysis. Primary outcome 
measures were: time to death, and time to the first occurrence of a composite of 
liver-related clinical events. The impact of treatment initiation relative to three dif-
ferent definitions of an elevated FIB4 level was estimated using a time-dependent 
Cox proportional hazards models. RESULTS: 187,860 patients met study require-
ments. Initiating treatment before FIB4> 1.00 reduced morbidity by 41% and death 
by 36%. Initiating treatment after FIB4> 1.00 remained effective but diminished the 
morbidity risk reduction achieved to 30%. However, outcomes were worse if treat-
ment initiation was delayed until after FIB4> 3.25. The risk reductions associated 
with treatment initiated before FIB4> 3.25 were 34% for the composite event and 
45% for death, but if initiated after FIB4> 3.25 were only 11% and 25%, respectively. 
The corresponding number needed to treat [NNT] to prevent one death, is 142 for 
treatment before FIB4> 1.00 and 180 if treatment is initiated before FIB4> 3.25. The 
estimated NNT is 128 if treated after FIB4> 1.00 but increases to 325 if treated after 
FIB4> 3.25. These detrimental effects of delaying treatment until FIB4> 3.25 were 
due to a reduction in the likelihood that treated patients would achieve viral load 
suppression as well as a reduced impact of viral load suppression on morbidity 
and mortality. CONCLUSIONS: Delaying treatment until after a patient’s FIB4 level 
exceeds 3.25 had a clear detrimental effect on treatment effectiveness.
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OBJECTIVES: The U.S. Advisory Committee on Immunization Practices (ACIP) rec-
ommends pneumococcal vaccination for adults younger than 65 years with condi-
tions at increased risk of pneumococcal disease. Yet there are limited real-world 
vaccination coverage data in these high-risk adults. This study aimed to examine 
studies. Patients with MDRAB had longer length of stay than control groups across 
all studies, though findings were not always statistically significant. Within ICU 
settings, however, the differences were significant in two of three studies. Mean 
costs tended to be higher for MDRAB patients, but methods varied across studies. 
Trends in mortality rates were mixed, with many studies reporting higher mortal-
ity rates associated with MDRAB versus controls, though few reported statistically 
significant differences. Receipt of appropriate therapy was associated with lower 
mortality, though not statistically significantly different. Few studies included detail 
on treatments provided. CONCLUSIONS: Across the limited available literature, 
there is a consistent trend towards worse outcomes (higher mortality, longer LOS, 
higher costs) among patients with MDRAB versus controls. However, given the vari-
ety of study types and settings as well as the lack of multivariate analyses in most 
studies, there is considerable need for future analysis.
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OBJECTIVES: The objective of this study was to characterize U.S. national trends 
of the incidence and cost of skin and soft tissue infections (SSTIs) in 2000 and 
2012. METHODS: We performed an analysis of nationally representative data from 
the Medical Expenditure Panel Surveys (MEPS) from 2000 and 2012. SSTIs were 
defined by Clinical Classification Software code 197. Expenditures in MEPS were 
defined as payments from all sources for hospital inpatient care, ambulatory care 
provided in offices and hospital outpatient facilities, care provided in emergency 
departments, and the retail purchase of prescribed medications. Expenditure data 
for 2000 were adjusted to 2012 dollars using the Consumer Price Index. RESULTS: 
The overall incidence of SSTIs increased 40% from 2.4 million in 2000 to 3.3 mil-
lion in 2012. From 2000 to 2012, the incidence of patients with at least one hospi-
tal visit for SSTI increased 38%, ambulatory visits increased 46%, and emergency 
department visits increased 56%. The total spent on the treatment of SSTIs tripled, 
from $4.4 billion in 2000 to $13.8 billion in 2012. This was largely attributed to an 
8-fold increase in ambulatory expenditures for SSTIs, from $975 million in 2000 to 
$7.9 billion in 2012. From 2000 to 2012, emergency department care expenditures 
increased 130%, inpatient hospitalization expenditures increased 56%, and retail 
prescription purchases increased 18%. The average expenditures for ambulatory 
visits increased 5-fold from $253 [standard error (SE) + $33] to $1,336 (SE + $240) 
per person, and average hospital expenditures increased 10% from $20,135 (SE + 
$3,997) to $22,706 (SE + $5,234) per person, between 2000 and 2012. CONCLUSIONS: 
The clinical and economic burden of SSTIs has significantly increased in the U.S., 
largely driven by a dramatic increase in the number and costs of SSTIs managed 
in the ambulatory setting.
PIN101
HIv ANtIretrovIrAL drug utILIzAtIoN ANd exPeNdItureS IN medIcAId 
1991-2014
Alshehri A.1, Seoane-Vazquez E.1, Schneider T.1, Rodriguez-Monguio R.2
1MCPHS University, Boston, MA, USA, 2University of Massachusetts, Amherst, Amherst, MA, USA
OBJECTIVES: Medicaid is the largest payer of HIV antiretrovirals (ARVs) in the US. 
To assess the trends in Medicaid utilization of ARVs and expenditures in the period 
1991-2014, and to compare the utilization and reimbursement rates of generic and 
brand ARVs in the study period. METHODS: ARVs data were gathered from the Food 
and Drug Administration website. Utilization and expenditure data were collected 
from the Center for Medicare and Medicaid Services website. The unit of analysis 
was the defined daily dose (DDD). Descriptive analyses were performed to assess the 
Medicaid ARVs utilization, reimbursement rate, and average reimbursement per 30 
DDD. RESULTS: Utilization of HIV ARVs in Medicaid increased over the study period 
from 21,000 30 DDD in Q1-1991 to 930,000 30 DDD in Q2-2014. Further, utilization 
of generic ARVs in Medicaid increased from 58 30 DDD in Q4 2004 to 93,000 30 DDD 
in Q2 2014. Likewise, Medicaid annual expenditures on ARVs increased from $5.2 
million in Q1 1991 to $702 million in Q2 2014. During the study period, 7 ARVs out of 
35 ARV products had generic competition in Medicaid program. The market share 
of generic ARVs increased from 8.2% in the first quarter of their launch to 89.5% by 
the end of the 3rd year after the generic entry into the market. The average Medicaid 
reimbursement rate for generics was 81% of the brand reimbursement rate at the 
first quarter of the generic launch, and decreased to 76% by the end of the 3rdyear 
after generic market entry. CONCLUSIONS: Several factors may explain Medicaid 
ARVs utilization and expenditures during the study period including the number 
and type (i.e. generics and brands) of FDA ARV approvals, the Medicaid generic 
drug utilization rate, changes in therapeutic guidelines, and states’ policies and 
regulations regarding Medicaid ARVs coverage and reimbursement mechanisms.
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OBJECTIVES: Pertussis (whooping cough) is an upper respiratory infection, caus-
ing uncontrollable and severe coughing. Pertussis outbreaks are associated to a 
substantial increase in resource use that may vary depending on the setting. This 
study aims at better understanding the economic burden of pertussis outbreaks, 
by setting. METHODS: A systematic review of literature on pertussis outbreaks was 
conducted, including references published between 2011 and 2014, using Medline, 
Embase, the Cochrane library and relevant websites as potential sources. All pop-
ulation-based studies reporting information about epidemiology, burden or costs 
of pertussis outbreaks were included, without geographical restriction. RESULTS: 
